Of interest, the recently reported de-escalation trial RTOG 1016, using 2 cycles of 100 mg/m2 cisplatin with altered fractionation radiotherapy in patients with low- and intermediate risk HPV-positive oropharyngeal cancer, showed superior outcome vs. the same radiotherapy plus weekly cetuximab (an anti-epidermal growth factor receptor [EGFR] monoclonal antibody approved for this indication) (41). Here, EGFR is linked to oropharynx cancer.